North America precision medicine market

Precision medicine is a highly effective, modern process of medical diagnosis and treatment of diseases using relevant data around a patient's genetic make-up, supported by environmental and behavioral data. North America is the pioneer in adopting technological innovations and advancements in the healthcare sector, which will aid the growth of the market in this region. North America is the highest revenue generating region for the precision medicine market. The increasing adoption of Internet of Medical Things (IoMT) and the use of technologies like gene sequencing, diagnostics, etc., have fueled the growth of precision medicine in this region and the market is at a mature stage in countries like the U.S. and Canada. According to Netscribes, the North American market is projected to expand at a compound annual growth rate (CAGR) of 11.04%, leading to a revenue of USD 36.25 Bn by 2023.

The North America precision medicine market is classified into three primary segments: based on ecosystem players: pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies and healthcare IT specialists/big data companies; based on therapeutics: cancer, cardiovascular, central nervous system, psychiatric disorder and infectious diseases; and based on technology: big data analytics, bioinformatics, gene sequencing, pharmacogenomics and companion diagnostics.
The diagnostic tools companies are expected to grow at the highest CAGR during the forecasted period of 2018-2023, owing to a rise in the demand for precision medicine. Diagnostic tools and treatments play an important role in the development of precision solutions to determine whether a drug is appropriate for a patient or not.
In the therapeutics segments, cancer therapeutics is expected to show a high growth rate through the forecast period 2018-2023.

Key growth factors

Due to technological advancements in the healthcare sector in North America, the precision medicine market is going to emerge in the coming years. In 2015, the then-President of the United States, Barrack Obama, announced the launch of the Precision Medicine Initiative for a bold new research effort to revolutionize methods to improve health and treat diseases. Therefore, the precision medicine market is going to grow during the forecast period due government initiatives and policies that encourage such technologies.

Threats and key players

Threat to personal information like genetic data, DNA and RNA data, etc., is considered to be a barrier to the growth of the precision medicine market. Thus, the adoption of precision medicine can hit roadblocks due to concerns regarding consumer privacy and data protection. Moreover, the approvals required by pharmaceutical companies from the U.S. Food & Drug Administration (FDA) for a particular drug or treatment is a time-consuming factor, which might be challenging and hinder the growth of the market.
The major players operating in the North America precision medicine market are Abbott, GE Healthcare, Johnson & Johnson, etc.

What's covered in the report?

1. Overview of the North America precision medicine market.
2. Market drivers and challenges in the North America precision medicine market.
3. Market trends in the North America precision medicine market.
4. Historical, current and forecasted market size data for the North America precision medicine market segmentation by ecosystem players (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies and healthcare IT specialists/big data companies) - by revenue (USD Bn).
5. Historical, current and forecasted market size data for the North America precision medicine market segmentation by therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder and infectious diseases) - by revenue (USD Bn).
6. Historical, current and forecasted market size data for the North America precision medicine market segmentation by technology (big data analytics, bioinformatics, gene sequencing, pharmacogenomics and companion diagnostics) - by revenue (USD Bn).
7. Historical, current and forecasted country- wise (U.S. and Canada) market size data (USD Bn) for the North America precision medicine market and its segmentations by ecosystem players (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies and healthcare IT specialists/big data companies), by therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder and infectious diseases), and by technology (big data analytics, bioinformatics, gene sequencing, pharmacogenomics and companion diagnostics).
8. Analysis of the competitive landscape and profiles of major companies operating in the market.

Why buy?

1. Understand the demand for precision medicine market to determine the viability of the market.
2. Determine the developed and emerging markets where precision medicine market is provided.
3. Identify the challenge areas and address them.
4. Develop strategies based on the drivers and trends and highlights for each of the segments.
5. Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed.
6. Recognize the key competitors of the market and respond accordingly.
7. Knowledge of the initiatives and growth strategies taken up by the major companies and decide the direction for further growth.
8. Define the competitive positioning by comparing the products and services with the key players in the market.

Customizations available

With the given market data, Netscribes offers customizations according to specific needs. Write to us at support@researchonglobalmarkets.com.

Chapter 1: Executive summary
1.1. Market scope and segmentation
1.2. Key questions answered
1.3. Executive summary

Chapter 2: North America precision medicine market - overview
2.1. North America market overview - market trends, drivers and challenges
2.2. Value chain analysis
2.3. Porter's Five Forces analysis
2.4. Market size - by ecosystem players (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies and healthcare IT specialists/big data companies)
2.4. a. Revenue from pharmaceuticals and biotech companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.4. b. Revenue from clinical laboratories - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.4. c. Revenue from diagnostic companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.4. d. Revenue from healthcare IT specialists/big data companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. Market size - by therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder and infectious diseases)
2.5. a. Revenue from cancer - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. b. Revenue from cardiovascular- Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. c. Revenue from central nervous system - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. d. Revenue from psychiatric disorder - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. e. Revenue from infectious diseases - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. Market size - by technology (big data analytics, bioinformatics, gene sequencing, pharmacogenomics and companion diagnostics)
2.6. a. Revenue from big data analytics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. b. Revenue from bioinformatics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. c. Revenue from gene sequencing - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. d Revenue from pharmacogenomics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. e Revenue from companion diagnostics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

Chapter 3: North America precision medicine market - by countries

3.1. The U.S.
3.1.1. Market overview - market trends, drivers and challenges
3.1.2. Market size - by ecosystem players (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies and healthcare IT specialists/big data companies)
3.1.2. a. Revenue from pharmaceuticals and biotech companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.2. b. Revenue from clinical laboratories - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.2. c. Revenue from diagnostic companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.2. d. Revenue from healthcare IT specialists/big data companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.3. Market size - by therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder and infectious diseases)
3.1.3. a. Revenue from cancer - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.3. b. Revenue from cardiovascular - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.3. c. Revenue from psychiatric disorder - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.3. d. Revenue from infectious diseases - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.4. Market size - by technology (big data analytics, bioinformatics, gene sequencing, pharmacogenomics and companion diagnostics)
3.1.4. a. Revenue from big data analytics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.4. b. Revenue from bioinformatics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.4. c. Revenue from gene sequencing - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.4. c. Revenue from pharmacogenomics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.1.4. c. Revenue from companion diagnostics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.2. Canada
3.2.1. Market overview- market trends, drivers and challenges
3.2.2. Market size - by ecosystem players (pharmaceuticals and biotech companies, clinical laboratories, diagnostic companies and healthcare IT specialists/big data companies)
3.2.2. a. Revenue from pharmaceuticals and biotech companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.2. b. Revenue from clinical laboratories - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.2. c. Revenue from diagnostic companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.2. d. Revenue from healthcare IT specialists/big data companies - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.3. Market size - By therapeutics (cancer, cardiovascular, central nervous system, psychiatric disorder and infectious diseases)
3.2.3. a. Revenue from cancer - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.3. b. Revenue from cardiovascular - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.3. c. Revenue from psychiatric disorder - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.3. d. Revenue from infectious diseases - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.4. Market size - By technology (big data analytics, bioinformatics, gene sequencing, pharmacogenomics and companion diagnostics)
3.2.4. a. Revenue from big data analytics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.4. b. Revenue from bioinformatics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.4. c. Revenue from gene sequencing - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.4. d Revenue from pharmacogenomics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2.4. e Revenue from companion diagnostics - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

Chapter 4: Competitive landscape

4.1. Abbott Laboratories
4.1.a. Company snapshot
4.1.b. Product offerings
4.1.c. Growth strategies
4.1.d. Initiatives
4.1.e. Geographical presence
4.1.f. Key numbers
4.2. GE Healthcare
4.2.a. Company snapshot
4.2.b. Product offerings
4.2.c. Growth strategies
4.2.d. Initiatives
4.2.e. Geographical presence
4.2.f. Key numbers

4.3. GlaxoSmithKline (GSK)
4.3.a. Company snapshot
4.3.b. Product offerings
4.3.c. Growth strategies
4.3.d. Initiatives
4.3.e. Geographical presence
4.3.f. Key numbers

4.4. Johnson & Johnson
4.4.a. Company snapshot
4.4.b. Product offerings
4.4.c. Growth strategies
4.4.d. Initiatives
4.4.e. Geographical presence
4.4.f. Key numbers

4.5. Pfizer
4.5.a. Company snapshot
4.5.b. Product offerings
4.5.c. Growth strategies
4.5.d. Initiatives
4.5.e. Geographical presence
4.5.f. Key numbers

4.6. Randox Laboratories
4.6.a. Company snapshot
4.6.b. Product offerings
4.6.c. Growth strategies
4.6.d. Initiatives
4.6.e. Geographical presence
4.6.f. Key numbers

4.7. Almac Group
4.7.a. Company snapshot
4.7.b. Product offerings
4.7.c. Growth strategies
4.7.d. Initiatives
4.7.e. Geographical presence
4.7.f. Key numbers

4.8. Novartis AG
4.8.a. Company snapshot
4.8.b. Product offerings
4.8.c. Growth strategies
4.8.d. Initiatives
4.8.e. Geographical presence
4.8.f. Key numbers

4.9. Teva Pharmaceuticals Limited
4.9.a. Company snapshot
4.9.b. Product offerings
4.9.c. Growth strategies
4.9.d. Initiatives
4.9.e. Geographical presence
4.9.f. Key numbers

4.10. Quest Diagnostics
4.10.a. Company snapshot
4.10.b. Product offerings
4.10.c. Growth strategies
4.10.d. Initiatives
4.10.e. Geographical presence
4.10.f. Key numbers

Chapter 5: Conclusion

Chapter 6: Appendix
6.1. List of tables
6.2. Research methodology
6.3. Assumptions
6.4. About Netscribes Inc.

Note: The Table of Contents (ToC) provided above contains the targeted coverage. The coverage is subject to change as we progress with the research

North America Vanadium Market Size, Share, Trends & Analysis by Grade Type (FeV40, FeV50, FeV60, FeV80), by Production Process (Aluminothermic Reduction Technique, Silicon Reduction Technique), by Application (Iron and Steel, Chemical, Titanium Alloys, Others), by End User (Automotive Chemical, Energy Storage, Others) and Region, with Forecasts from 2024 to 2034....

Market Overview The North America Vanadium Market is expected to experience substantial growth from 2024 to 2034, driven by increasing demand from various sectors such as iron and steel, energy storage, and chemicals. The market is projected to grow from USD XXX.XX million in 2024 to US...

North America Vascular Closure Devices Market Size, Share, Trends & Analysis by Type (Active Approximators, Passive Approximators, External Hemostatic Devices), by Access (Femoral Access, Radial Access), by Procedure (Interventional Cardiology, Interventional Radiology) and Region, with Forecasts from 2024 to 2034....

Market Overview The North America Vascular Closure Devices (VCD) Market is anticipated to witness significant growth from 2024 to 2034, driven by the increasing volume of minimally invasive cardiovascular procedures, rising prevalence of cardiovascular diseases, and advancements in vasc...

Asia Pacific Nuclear Medicine Market Size, Share, Trends & Analysis by Product (Diagnostics (SPECT, PET), Therapeutics (Alpha Emitters, Beta Emitters)), by Application (Neurology, Cardiology, Oncology, Others), by End User (Hospitals & Clinics, Diagnostic Centers, Others) and Region, with Forecasts from 2024 to 2034....

Market Overview The Asia Pacific Nuclear Medicine Market is poised for significant growth from 2024 to 2034, driven by advancements in nuclear imaging technologies, increased application in various medical fields, and rising healthcare investments across the region. The market is expect...

Europe Nuclear Medicine Market Size, Share, Trends & Analysis by Product (Diagnostics (SPECT, PET), Therapeutics (Alpha Emitters, Beta Emitters)), by Application (Neurology, Cardiology, Oncology, Others), by End User (Hospitals & Clinics, Diagnostic Centers, Others) and Region, with Forecasts from 2024 to 2034....

Market Overview The Europe Nuclear Medicine Market is expected to witness substantial growth from 2024 to 2034, driven by advancements in nuclear imaging technology, increasing demand for early and accurate diagnosis, and the growing prevalence of chronic diseases such as cancer and car...

North America Nuclear Medicine Market Size, Share, Trends & Analysis by Product (Diagnostics (SPECT, PET), Therapeutics (Alpha Emitters, Beta Emitters)), by Application (Neurology, Cardiology, Oncology, Others), by End User (Hospitals & Clinics, Diagnostic Centers, Others) and Region, with Forecasts from 2024 to 2034....

Market Overview The North America Nuclear Medicine Market is poised for substantial growth between 2024 and 2034, driven by advancements in diagnostic imaging and therapeutic applications, rising prevalence of chronic diseases, and increasing adoption of nuclear medicine techniques. The...

Global Nuclear Medicine Market Size, Share, Trends & Analysis by Product (Diagnostics (SPECT, PET), Therapeutics (Alpha Emitters, Beta Emitters)), by Application (Neurology, Cardiology, Oncology, Others), by End User (Hospitals & Clinics, Diagnostic Centers, Others) and Region, with Forecasts from 2024 to 2034....

Market Overview The Global Nuclear Medicine Market is projected to experience significant growth from 2024 to 2034, driven by technological advancements in diagnostic imaging and the increasing demand for targeted radiopharmaceutical therapies. Valued at USD XX.XX billion in 2024, the m...

North America Anti-Pollution Mask Market Size, Share, Trends & Analysis by Type (Disposable, Reusable), by Filter Type (Combination Filter, Gas and Odour Filter, Particulate Filter), by Distribution Channel (Online, Offline) and Region, with Forecasts from 2024 to 2034....

Market Overview The North America Anti-Pollution Mask Market is anticipated to witness significant growth from 2024 to 2034, driven by increasing awareness of air quality issues and the rising prevalence of respiratory diseases. The market, encompassing a wide range of anti-pollution ma...

North America Ethnic Wear Market Size, Share, Trends & Analysis by End User (Men, Women, Children), by Type (Fusion Wear, Traditional Wear), by Distribution Channel (Online, Offline) and Region, with Forecasts from 2024 to 2034....

Market Overview The North America Ethnic Wear Market is set to experience considerable growth from 2024 to 2034, driven by evolving fashion trends and a growing appreciation for cultural heritage. The market, which includes a diverse range of ethnic apparel, is projected to reach USD XX...

North America FinTech Investment Market Size, Share, Trends & Analysis by Product Type (P2P Lending, Online Acquiring & Mobile Wallets, Personal Finance Management, MSME Services, MPOS, Mobile First Banking, Bitcoin, Crowdfunding, Others), by Technology (Internet of Things (IoT), Artificial Intelligence, 5G, Big Data, Blockchain, Open Banking, Others) and Region, with Forecasts from 2024 to 2034....

Market Overview The North America FinTech Investment Market is set to experience substantial growth from 2024 to 2034, driven by an accelerated adoption of innovative financial technologies across various sectors. The market, which encompasses investments in a wide range of FinTech solu...

North America Airport Asset Tracking Market Size, Share, Trends & Analysis by Offering (Hardware, Software), by Asset Type (Fixed Assets, Portable Assets, Mobile Assets) and Region, with Forecasts from 2024 to 2034....

Market Overview The North America Airport Asset Tracking Market is set for significant growth from 2024 to 2034, driven by advancements in asset tracking technologies and increased focus on operational efficiency and safety within airport environments. The market is projected to grow fr...